OS Therapies Agrees to Acquire All Listeria Monotygenes-based
OS Therapies, a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based...
